ExploreWatchlistsPricing
  1. JP-listed companies
  2. AnGes, Inc.
  3. Financials
  4. Return on equity (%)

AnGes, Inc. (4563)

Market cap
¥22.6B
P/E ratio
-2.2x
AnGes develops gene medicines and nucleic acid treatments, while providing genetic screening tests for rare disorders through its clinical research laboratory.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndReturn on equity (%) (Million JPY)YoY (%)
Dec 31, 2025-195.8-1.63%
Dec 31, 2024-199.1+656.63%
Dec 31, 2023-26.3-38.25%
Dec 31, 2022-42.6+11.11%
Dec 31, 2021-38.3+103.77%
Dec 31, 2020-18.8-50.36%
Dec 31, 2019-37.9-28.16%
Dec 31, 2018-52.8-47.50%
Dec 31, 2017-100.5-14.88%
Dec 31, 2016-118.1+70.37%
Dec 31, 2015-69.3+64.98%
Dec 31, 2014-42

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat